LB Pharmaceuticals (NASDAQ:LBRX) Price Target Raised to $40.00

LB Pharmaceuticals (NASDAQ:LBRX) had its price objective lifted by Stifel Nicolaus from $35.00 to $40.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other analysts also recently weighed in on the company. Weiss Ratings reiterated a “sell (e)” rating on shares of LB Pharmaceuticals in a research report on Monday, December 29th. Roth Mkm assumed coverage on shares of LB Pharmaceuticals in a report on Friday, January 9th. They issued a “buy” rating and a $31.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $35.00.

LB Pharmaceuticals Stock Performance

Shares of NASDAQ LBRX opened at $23.84 on Friday. The business has a 50 day simple moving average of $23.59. LB Pharmaceuticals has a fifty-two week low of $13.36 and a fifty-two week high of $27.55. The stock has a market capitalization of $683.49 million and a P/E ratio of -39.08.

LB Pharmaceuticals (NASDAQ:LBRX) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.45) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.45).

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Federated Hermes Inc. purchased a new position in shares of LB Pharmaceuticals during the third quarter valued at $142,000. JPMorgan Chase & Co. bought a new position in LB Pharmaceuticals in the third quarter worth approximately $16,305,000. TD Asset Management Inc bought a new stake in LB Pharmaceuticals during the 3rd quarter valued at $581,000. Monashee Investment Management LLC bought a new stake in LB Pharmaceuticals during the 3rd quarter valued at $632,000. Finally, Jefferies Financial Group Inc. purchased a new position in shares of LB Pharmaceuticals in the 3rd quarter valued at $207,000.

Key LB Pharmaceuticals News

Here are the key news stories impacting LB Pharmaceuticals this week:

• Positive Sentiment: Initiated pivotal Phase 3 NOVA-2 trial for LB-102 in acute schizophrenia, moving the program into late‑stage development and de‑risking the clinical pathway. LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102
• Positive Sentiment: New Phase 2 (NOVA-1) analyses presented at SIRS show LB-102 produced statistically significant, likely direct improvements in cognitive performance versus placebo — a clinically meaningful differentiation if confirmed in Phase 3. LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial
• Positive Sentiment: Multiple SIRS presentations and encore sessions underline broad evidence across symptom domains (positive, negative, cognitive), increasing the perceived clinical value of LB-102. LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial (GlobeNewswire)
• Positive Sentiment: Stifel raised its price target from $35 to $40 and maintains a Buy rating — a notable analyst vote of confidence that can support upside if clinical and regulatory progress continues. Stifel raises price target
• Positive Sentiment: Strong cash position: ~$295.2M in cash, equivalents and investments as of 12/31/25 plus ~$100M private placement; company says runway into Q2 2029 — reduces near‑term financing risk for ongoing trials. Q4 and FY2025 Results and Corporate Update
• Neutral Sentiment: Q4 EPS of ($0.45) matched consensus — earnings met expectations but did not provide an upside catalyst; full financials and guidance appear consistent with the company’s stated runway. Quarterly Results PDF
• Negative Sentiment: Cautionary forward‑looking statements and standard clinical/regulatory risks remain — Phase 3 outcomes, approval risk and commercialization execution are not guaranteed, and the company has a limited operating history and historical losses. Risk Factors and Cautionary Note

LB Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.